A Phase 3 interventional study of Gadopiclenol and Comparator (gadobutrol) in Lesion in Body Region and CNS Lesion, sponsored by Guerbet. Completed at 27 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
GDX-44-014 - GDX-101 study was conducted in Japan including 2 cohorts (adult cohort for adult population and pediatric cohort for pediatric population), with different designs:
The primary objective was to demonstrate the non-inferiority of gadopiclenol-enhanced MRI at 0.05 mmol/kg body weight (BW) compared to gadobutrol-enhanced MRI at 0.1 mmol/kg BW in terms of lesion visualization for adult patients referred for contrast-enhanced MRI of Central Nervous System (CNS) or Body regions.
Adult cohort:
The trial included a maximum of 5 visits and the record of patient's diagnosis as standard of truth:
Pediatric cohort:
The inclusions was divided into 4 age groups: patients from birth to 23 months of age inclusive, patients from 2 to 6 years, patients from 7 to 11 years and patients from 12 to 17 years. The recruitment in the 3 older groups of pediatric patients could be conducted in parallel with adult patients' enrolment. The decision to start the inclusion in the group of patients aged from birth to 23 months was taken by the Trial Safety Review Board (TSRB).
The trial included a maximum of 3 visits and the record of patient's diagnosis as standard of truth:
All Patients:
Images were assessed off-site in a centralized manner.
Pediatric group for pharmacokinetics (PK) analysis :
Up to 24 patients of the pediatric cohort would be included in gadopiclenol PK profile assessment.
The approach implemented for PK analyses allowed sparse blood sampling only and was selected to minimize the clinical burden to children.
All cohorts :
During the trial, the safety of the patients was monitored and assessed based on the reporting of adverse events (AEs), including vital signs, ECG for pediatric patients and clinical laboratory parameters (blood samples).
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria for all patients:
Inclusion criteria for adult patients:
Inclusion criteria for pediatric patients:
Female or male pediatric patient from birth to 17 years. For patients aged from birth to 27 days, only term newborn infants were eligible.
Patients might not have reached the age of 18 years at the MRI examination.
Exclusion Criteria:
Non-inclusion criteria for all patients:
All Female patient of with a positive urine pregnancy test done within 1 day prior to each contrast agent administration and not able / not willing to use highly effective birth-controlled method during the trial duration.
Female had to have effective medically approved until the last trial visit, if of childbearing potential or with amenorrhea for less than 12 months or must be surgically sterilized or (> 2 years amenorrhea).
Non-inclusion criteria for adult patients:
Non-inclusion criteria for pediatric patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cross-over study. For each patient in this arm, he (she) performed the first contrast-enhanced MRI with gadopiclenol as contrast agent. After a washout period of 2-14 days, the patient performed the second contrast-enhanced MRI with gadobutrol as contrast agent. Gadopiclenol and gadobutrol were injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and might vary depending on scanned organ/region and age of patients.
Drug: Gadopiclenol · Drug: Comparator (gadobutrol)
Cross-over study. For each patient in this arm, he (she) performed the first contrast-enhanced MRI with gadobutrol as contrast agent. After a washout period of 2-14 days, the patient performed the second contrast-enhanced MRI with gadopiclenol as contrast agent. Gadobutrol and gadopiclenol were injected as a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector. The injection rate should be identical for both products and might vary depending on scanned organ/region and age of patients.
Drug: Gadopiclenol · Drug: Comparator (gadobutrol)
Pediatric patients underwent one MRI examination with gadopiclenol. Gadopiclenol was injected in a single intravenous (IV) bolus injection at a recommended rate of approximately 2 mL/second followed by a 0.9% saline flush via manual injection or power injector.
Drug: Gadopiclenol
Dose/volume: Gadopiclenol administered was calculated based on patient's weight at the dose of 0.05 mmol/kg BW
Also known as: Elucirem/Vueway
Dose/volume of comparator: Gadobutrol administered was calculated based on patient's weight at the dose of 0.1 mmol/kg BW.
Also known as: Gadovist/Gadavist
Lesion Visualization on Paired Images: Border Delineation
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Delineation of the lesion border was defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion was assessed through the following scale: 1. = None 2. = Moderate 3. = Good 4. = Excellent: For this co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Lesion Visualization on Paired Images: Internal Morphology
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Internal morphology of the lesion included an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion was assessed through the following scale: 1. = Poor 2. = Moderate 3. = Good 4. = Excellent For this co-primary criterion "internal morphology", a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Lesion Visualization on Paired Images: Degree of Contrast Enhancement
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. The criterion "degree of contrast enhancement" was a qualitative assessment (not based on signal intensity measurement) according to the following scale: 1. = No: no enhancement 2. = Moderate: weakly enhanced 3. = Good: clearly enhanced 4. = Excellent: clearly and brightly enhanced For each co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
Time frame: At each MRI exam: the first MRI at Day 1 and the second MRI performed after a wash out period of 2 to 14 days (adult cohort)
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Border Delineation
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol as contrast agent. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
Time frame: At MRI exam, Day 1 (pediatric cohort)
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Internal Morphology
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
Time frame: At MRI exam, Day 1 (pediatric cohort)
Pediatric Cohort: Lesion Visualization on Paired Images Compared With Pre Images: Degree of Contrast Enhancement
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
Time frame: At MRI exam, day 1 (pediatric cohort)
| Milestone | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol |
|---|---|---|---|
| Started | 100 | 100 | 40 |
| Completed | 99 | 98 | 40 |
| Not completed | 1 | 2 | 0 |
| Withdrew: Inclusion criteria not met | 1 | 0 | 0 |
| Withdrew: Other reason | 0 | 2 | 0 |
| Milestone | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol |
|---|---|---|---|
| Started | 99 | 98 | 0 |
| Completed | 96 | 96 | 0 |
| Not completed | 3 | 2 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Other reason | 0 | 1 | 0 |
| Milestone | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol |
|---|---|---|---|
| Started | 96 | 96 | 0 |
| Completed | 96 | 96 | 0 |
| Not completed | 0 | 0 | 0 |
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Delineation of the lesion border was defined as the distinction of lesion from surrounding tissues, structures, or edema, and the detection of extent of the lesion. This criterion was assessed through the following scale: 1. = None 2. = Moderate 3. = Good 4. = Excellent: For this co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
| score on a scale | Patients With Gadopiclenol Paired Images | Patients With Gadobutrol Paired Images |
|---|---|---|
| Border delineation - Reader A | 3.81 ± 0.04 | 3.75 ± 0.04 |
| Border delineation - Reader B | 3.34 ± 0.05 | 3.24 ± 0.05 |
| Border delineation - Reader C | 3.07 ± 0.05 | 3.00 ± 0.05 |
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. Internal morphology of the lesion included an identification of lesion architecture and the intra-lesion features such as necrosis, hemorrhage, and vascularity. This criterion was assessed through the following scale: 1. = Poor 2. = Moderate 3. = Good 4. = Excellent For this co-primary criterion "internal morphology", a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
| score on a scale | Patients With Gadopiclenol Paired Images | Patients With Gadobutrol Paired Images |
|---|---|---|
| Internal morphology - Reader A | 3.71 ± 0.04 | 3.65 ± 0.04 |
| Internal morphology - Reader B | 3.20 ± 0.07 | 3.17 ± 0.07 |
| Internal morphology - Reader C | 3.24 ± 0.05 | 3.14 ± 0.05 |
The lesion visualization criterion (per patient) was based on 3 co-primary criteria (border delineation, internal morphology and degree of contrast enhancement) assessed by 3 independent off-site blinded readers. The IBR recorded each of the 3 co-primary criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images performed with gadopiclenol and Paired (pre+post) images performed with gadobutrol. The criterion "degree of contrast enhancement" was a qualitative assessment (not based on signal intensity measurement) according to the following scale: 1. = No: no enhancement 2. = Moderate: weakly enhanced 3. = Good: clearly enhanced 4. = Excellent: clearly and brightly enhanced For each co-primary criterion, a mean of scores for each patient and for each reader was calculated and ranged from 1 to 4.
| score on a scale | Patients With Gadopiclenol Paired Images | Patients With Gadobutrol Paired Images |
|---|---|---|
| Degree of contrast enhancement - Reader A | 3.70 ± 0.07 | 3.59 ± 0.07 |
| Degree of contrast enhancement - Reader B | 3.18 ± 0.07 | 3.06 ± 0.07 |
| Degree of contrast enhancement - Reader C | 3.04 ± 0.07 | 3.03 ± 0.07 |
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol as contrast agent. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
| mean of a score (on a scale) per patient | Pediatric Cohort: Patients With Paired Images | Pediatric Cohort: Patients With Pre-images |
|---|---|---|
| Border delineation - Reader A | 3.72 ± 0.13 | 1.88 ± 0.13 |
| Border delineation - Reader B | 3.33 ± 0.13 | 2.57 ± 0.13 |
| Border delineation - Reader C | 3.07 ± 0.14 | 2.34 ± 0.14 |
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
| mean of a score (on a scale) per patient | Pediatric Cohort: Patients With Paired Images | Pediatric Cohort: Patients With Pre-images |
|---|---|---|
| Internal morphology - Reader A | 3.76 ± 0.12 | 1.60 ± 0.12 |
| Internal morphology - Reader B | 3.33 ± 0.14 | 2.26 ± 0.14 |
| Internal morphology - Reader C | 3.15 ± 0.17 | 2.43 ± 0.17 |
The lesion visualization criterion based on 3 co-criteria: border delineation, internal morphology and degree of contrast enhancement assessed on the images acquired during the MRI performed with gadopiclenol assessed by 3 independent off-site blinded readers (IBR). The IBR recorded each of the 3 co-criteria for up to 10 largest and most enhancing lesions on Paired (pre+post) images and Pre images performed with gadopiclenol. Definitions of each co-criteria and score calculation were provided in the section for primary outcome measure.
| Mean of a score (on a scale) per patient | Pediatric Cohort: Patients With Paired Images | Pediatric Cohort: Patients With Pre-images |
|---|---|---|
| Degree of contrast enhancement - Reader A | 3.68 ± 0.09 | 1.00 ± 0.09 |
| Degree of contrast enhancement - Reader B | 3.30 ± 0.11 | 1.00 ± 0.11 |
| Degree of contrast enhancement - Reader C | 3.27 ± 0.12 | 1.00 ± 0.12 |
Collected over For adult cohort, adverse event (AE) data were collected from informed consent signature to one day after the second MRI examination. For pediatric cohort, AE data were collected from informed consent signature to one day after the only MRI examination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adult Cohort: TEAEs Occurring During and or After Gadopiclenol Administration | 0/195 (0%) | 1/195 (0.5%) | 26/195 (13.3%) |
| Adult Cohort: TEAEs Occurring During and or After Gadobutrol Administration | 0/194 (0%) | 3/194 (1.5%) | 24/194 (12.4%) |
| Pediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration | 0/40 (0%) | 0/40 (0%) | 4/40 (10%) |
| Event | Adult Cohort: TEAEs Occurring During and or After Gadopiclenol Administration | Adult Cohort: TEAEs Occurring During and or After Gadobutrol Administration | Pediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration |
|---|---|---|---|
| Animal BiteInjury, poisoning and procedural complications | 0/195 | 1/194 | 0/40 |
| Intracranial Tumour HaemorrhageNervous system disorders | 0/195 | 1/194 | 0/40 |
| IleusGastrointestinal disorders | 0/195 | 1/194 | 0/40 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/195 | 1/194 | 0/40 |
| Cerebral InfarctionNervous system disorders | 1/195 | 0/194 | 0/40 |
| Event | Adult Cohort: TEAEs Occurring During and or After Gadopiclenol Administration | Adult Cohort: TEAEs Occurring During and or After Gadobutrol Administration | Pediatric Cohort: TEAEs Occurring During and or After Gadopiclenol Administration |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/195 | 5/194 | 0/40 |
| LeukopeniaBlood and lymphatic system disorders | 0/195 | 0/194 | 1/40 |
| NeutropeniaBlood and lymphatic system disorders | 0/195 | 0/194 | 1/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/195 | 0/194 | 1/40 |
| GastroenteritisInfections and infestations | 0/195 | 0/194 | 1/40 |
| Blood creatinine increasedInvestigations | 0/195 | 0/194 | 1/40 |
| HypochloraemiaMetabolism and nutrition disorders | 0/195 | 0/194 | 1/40 |
| HyponatraemiaMetabolism and nutrition disorders | 0/195 | 0/194 | 1/40 |
| HypertensionVascular disorders | 0/195 | 0/194 | 1/40 |
| NauseaGastrointestinal disorders | 1/195 | 2/194 | 0/40 |
The analysis was based on participants. Adult cohort: For the primary analysis, the analysis population was patients who had matching lesions on both Paired (combined unenhanced and contrast-enhanced) images performed with gadopiclenol and Paired images performed with gadobutrol. Per Protocol Set (PPS): 92 in the Arm 1 and 96 in the Arm 2. Pediatric cohort: 40 patients having matching lesions on both paired images and pre-contrast images with gadopiclenol as contrast agent (Full analysis Set)
| Age, Continuous(years) | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol | Total |
|---|---|---|---|---|
| Mean | 67.2 ± 11.9 | 63.8 ± 14.5 | 8.43 ± 5.26 | 65.4 ± 13.3 |
| Sex: Female, Male(Participants) | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol | Total |
|---|---|---|---|---|
| Female | 38 | 43 | 19 | 100 |
| Male | 54 | 53 | 21 | 128 |
| Race (NIH/OMB)(Participants) | Adult Cohort Arm 1: First MRI With Gadopiclenol and Second MRI With Gadobutrol | Adult Cohort Arm 2: First MRI With Gadobutrol and Second MRI With Gadopiclenol | Pediatric Cohort: One MRI With Gadopiclenol | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 92 | 96 | 40 | 228 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2023 to primary completion in May 2025, 21 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol